conophylline and Endomyocardial-Fibrosis

We studied the effects and mechanisms of action of conophylline in different concentrations in the original in vitro model of myocardial fibrosis (treatment of cardiac fibroblasts isolated form the hearts of newborn rats with angiotensin II). Viability, collagen content, and expression of related protein in cardiac fibroblasts were assessed using the MTT-test, Sircol assay, and Western blotting, respectively. Conophylline markedly protected the cultured cells against the development of angiotensin II-induced fibrosis, which was seen from reduced viability of fibroblasts, decreased collagen content, and down-regulation of the expression of α-smooth muscle actin (α-SMA). Conophylline did not affect the TGF-β pathway altered by angiotensin II, but markedly decreased the level of bone morphogenetic protein-4 (BMP4) enhanced by angiotensin II and BMP4 itself. Conophylline produced no effect on phosphorylation of α-SMA and Smad homologue-1/5/8, the classic BMP4 downstream pathway elements, but reduced the level of c-Jun N-terminal kinase (JNK) elevated by BMP4. Conophylline did not inhibit the development of myocardial fibrosis in the presence of JNK activator anisomycin. Thus, conophylline inhibited angiotensin II-provoked myocardial fibrosis via the BMP4/JNK pathway.

Topics: Angiotensin II; Animals; Animals, Newborn; Antifibrotic Agents; Bone Morphogenetic Protein 4; Collagen; Endomyocardial Fibrosis; Fibroblasts; Gene Expression Regulation; MAP Kinase Kinase 4; Models, Biological; Myocardium; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Primary Cell Culture; Rats; Rats, Wistar; Signal Transduction; Smad1 Protein; Smad5 Protein; Smad8 Protein; Transforming Growth Factor beta1; Vinca Alkaloids